Clinical Trial Update: Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol [Phase 3]

View source ↗

Summary

The Phase 3 clinical trial of Drisapersen for Duchenne muscular dystrophy has been withdrawn by sponsor GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Drisapersen (drisapersen)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Muscular Dystrophies | Phase 3 | Status: WITHDRAWN